According to an NBC News article, an FDA panel rejected Biogen’s experimental Alzheimer’s drug due to a lack of “strong evidence” it works. The drug is aducanumab, and it has received ample criticism after experts identified “red flags” in the data, which didn’t show any initial benefits.
FDA Panel Rejects New Alzheimer’s Drug
Biogen’s experimental Alzheimer’s drug lacks enough evidence for FDA approval.
Nov 11, 2020
INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
Read More